FDA Invites Chatter on Rare Disease Gadget Info Gathering
Published Date: 12/9/2025
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about special medical devices made for rare diseases affecting fewer than 8,000 people in the U.S. This helps speed up access to these devices by easing some rules, with no extra costs expected. Comments are open until January 8, 2026, so anyone interested can share their thoughts!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Faster access for rare‑disease devices
The FDA’s Humanitarian Use Device (HUD) program lets a device be exempted from effectiveness requirements when it is for a disease or condition that affects no more than 8,000 people in the United States. That exemption is intended to help speed access to devices for these rare conditions by allowing marketing under a Humanitarian Device Exemption (HDE).
No‑profit rule for HUDs limits sales
HUDs approved under an HDE generally may not be sold for profit; they can only be sold for amounts that do not exceed research, development, fabrication, and distribution costs. That profit prohibition applies unless narrow statutory exceptions apply (see pediatric/ADN rules).
Pediatric exception and ADN profit pathway
The statute allows an HUD approved under an HDE to be sold for profit if the device is intended and labeled for pediatric patients or meets other narrow pediatric-related criteria. The Secretary assigns an annual distribution number (ADN) that estimates how many devices are reasonably needed for a population of 8,000; HDE holders must notify FDA immediately if distributions in a calendar year exceed the ADN and may petition to modify the ADN.
Reporting and paperwork burden on applicants
The FDA is renewing its information collection (OMB Control No. 0910-0332) for HUD/HDE submissions and estimates a total annual hour burden of 22,584 hours across respondents. Specific burdens shown include an HDE application averaging 328 hours and periodic reports averaging 120 hours each; FDA states there are no capital costs or operating and maintenance costs associated with this collection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-22277, Agency Information Collection Activities; Proposed Collection; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA wants to hear from food businesses about new rules for keeping extra records to track certain foods better. This helps keep food safe and makes it easier to find problems fast. If you’re involved in food production or handling, you have until February 9, 2026, to share your thoughts—no extra costs yet, just a chance to comment!
Next: 2025-22280, New Postal Products
The Postal Service wants to add or change special deals for competitive mail services, and the Postal Regulatory Commission is asking the public to share their thoughts by December 11, 2025. These changes could affect businesses using these mail services and might impact pricing or options soon. It’s a chance to weigh in on how mail deals evolve!